Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
Our study provides valuable pharmacological insights for early clinical intervention in managing ADRs and offers significant clinical benefits for HCC patients undergoing combination therapy with atezolizumab and bevacizumab.
Authors
- Yanling Yuan
- Wen Yang (ORCID: https://orcid.org/0009-0006-3748-7379)
- Wanming He
- Lihua Tong (ORCID: https://orcid.org/0000-0002-3981-7718)
- Xingxi Pan (ORCID: https://orcid.org/0000-0003-4109-5408)
- Xia Yang (ORCID: https://orcid.org/0000-0003-2183-0284)
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3389/fphar.2025.1448095
- Citations
- 2
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 5.26